About Mannin Research
Mannin Research is a company based in Toronto (Canada) founded in 2012 was acquired by QBioMed in October 2015. Mannin Research offers products and services including Glaucoma Eye Drop, Tie2 Activator, and Proprietary Research Platform. Mannin Research operates in a competitive market with competitors including Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Calliditas Therapeutics, among others.
- Headquarter Toronto, Canada
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mannin Research Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$7.5 M (USD), Grant
Nov 05, 2019
-
Investors
National Research Council Canada
& 1 more
-
Employee Count
Not available
-
Acquired by
QBioMed
(Oct 30, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Mannin Research
Mannin Research offers a comprehensive portfolio of products and services, including Glaucoma Eye Drop, Tie2 Activator, and Proprietary Research Platform.
Eye drop designed to reduce intra-ocular pressure for glaucoma treatment
Compound for protecting kidney in acute kidney injury cases
Platform for developing new vascular disease therapeutics
Funding Insights of Mannin Research
Investors in Mannin Research
Mannin Research has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include National Research Council Canada and QBioMed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Scientific and technological research is conducted for Canada's benefit.
|
Locked | Locked | Locked | |
|
Chemotherapeutic agents for hepatocellular carcinoma are developed using uttroside B.
|
Locked | Locked | Locked |
Investor details for Mannin Research
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mannin Research
Investment portfolio details for Mannin Research
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Mannin Research
Detailed financials for Mannin Research
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mannin Research Comparisons
Peer comparison for Mannin Research
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Mannin Research
Mannin Research operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Calliditas Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for cardiovascular and autoimmune diseases are developed.
|
|
| Locked | Locked | Locked |
Specialized drugs are developed for genetic heart diseases.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
|
| Locked | Locked | Locked |
Provider of small molecule based drug for inflammatory kidney disease
|
|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
Detailed competitors of Mannin Research
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mannin Research
Complete news archive for Mannin Research
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mannin Research
Mannin Research was founded in 2012 and raised its 1st funding round 5 years after it was founded.
Mannin Research is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Mannin Research was founded in 2012 and is based in Toronto, Canada. Focus is placed on the biotechnology sector, where therapeutics for vascular diseases are developed. The lead candidate, MAN-01, is a small-molecule eye drop in pre-clinical stages for Primary Open Angle Glaucoma, targeting reduction of intraocular pressure. A second candidate for cystic kidney disease remains in the discovery stage. Operations center on advancing these programs toward clinical applications.
Mannin Research's top competitors include Tenaya Therapeutics, Cellino and MyoKardia.
Mannin Research offers Glaucoma Eye Drop, Tie2 Activator, and Proprietary Research Platform.
Mannin Research has 2 investors. Key investors include National Research Council Canada, and QBioMed.